Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2006 | 12-2005 | 12-2004 | 12-2003 | 12-2002 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 26,124 | 27,606 | 41,171 | 18,187 | 34,838 |
| Marketable Securities | 81,040 | 100,304 | 92,578 | 106,441 | 94,699 |
| Receivables | 40,972 | 28,698 | 26,462 | 31,479 | 27,378 |
| Inventories | 22,644 | 30,603 | 32,415 | 34,292 | 13,402 |
| Income taxes - deferred | 4,725 | 3,968 | N/A | N/A | N/A |
| Other current assets | 1,500 | 5,376 | 5,627 | 0 | 0 |
| TOTAL | $182,620 | $202,733 | $202,146 | $195,653 | $173,093 |
| Non-Current Assets | |||||
| PPE Net | 153,202 | 151,078 | 145,753 | 146,639 | 72,518 |
| Investments And Advances | 956 | 956 | 956 | 2,191 | 19,215 |
| Intangibles | 37,912 | 27,181 | 26,948 | 45,105 | 21,985 |
| Other Non-Current Assets | 803 | 1,202 | 1,089 | 1,357 | 15,925 |
| TOTAL | $192,873 | $180,417 | $174,746 | $195,292 | $129,643 |
| Total Assets | $375,493 | $383,150 | $376,892 | $390,945 | $302,736 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 4,541 | 4,536 | 4,526 | 4,521 | 215 |
| Accounts payable and accrued liabilities | 13,502 | 10,473 | 9,621 | 8,776 | 4,201 |
| Accrued Expenses | 4,927 | 4,916 | 5,299 | 6,568 | 3,878 |
| Other current liabilities | N/A | N/A | N/A | N/A | 60 |
| TOTAL | $32,688 | $39,928 | $22,381 | $21,044 | $9,960 |
| Non-Current Liabilities | |||||
| Long Term Debt | 13,993 | 18,521 | 48,603 | 53,129 | 5,281 |
| Deferred Revenues | 8,285 | 12,537 | 2,089 | 1,179 | 1,116 |
| Other Non-Current Liabilities | 711 | 2,592 | 3,435 | 3,430 | 0 |
| TOTAL | $24,350 | $30,161 | $59,035 | $67,966 | $10,409 |
| Total Liabilities | $57,038 | $70,089 | $81,416 | $89,010 | $20,369 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 32,681 | 32,407 | 31,937 | 31,661 | 32,024 |
| Common Shares | 347 | 345 | 340 | 337 | 334 |
| Retained earnings | 161,320 | 159,137 | 142,816 | 154,507 | 124,250 |
| Other shareholders' equity | 661 | -2,487 | -288 | -274 | -859 |
| TOTAL | $318,455 | $313,061 | $295,476 | $301,935 | $282,367 |
| Total Liabilities And Equity | $375,493 | $383,150 | $376,892 | $390,945 | $302,736 |